Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ViRTUE Study: Paricalcitol with RAAS blockade and low sodium diet in chronic kidney disease
2009-016159-23Phase 3
Key facts
- Status
- Active
- Start
- Oct 2009
- Countries
- 1
- Sponsor
- University Medical Center Groningen
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Drugs
- paricalcitol
- Conditions
- chronic kidney disease (CKD)
01
Overview
Phase 3 trial of paricalcitol in chronic kidney disease (CKD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: proteinuria. Started Oct 2009; status: active.
02
Design
2 armsParicalcitol + ramipril + low sodium diet
Adjunctive paricalcitol on top of RAAS blockade with ramipril and dietary sodium restriction.
Ramipril + low sodium diet
Active control arm receiving RAAS blockade with ramipril and dietary sodium restriction without paricalcitol.
03
Who it enrols
Adult male and female patients with chronic kidney disease on RAAS blockade and low sodium diet; inability to meet inclusion criteria is an exclusion.
04
Endpoints
Primary
proteinuria
Secondary
reactive renin response
Beyond the preview
Go deeper on 2009-016159-23.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016159-23.